ZBIO
Zenas BioPharma, Inc. Common Stock
NASDAQ: ZBIO · HEALTHCARE · BIOTECHNOLOGY
$17.55
-2.55% today
Updated 2026-04-29
Market cap
$1.09B
P/E ratio
—
P/S ratio
109.46x
EPS (TTM)
$-8.44
Dividend yield
—
52W range
$9 – $45
Volume
0.7M
Zenas BioPharma, Inc. Common Stock (ZBIO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $50.00M | $5.00M | $10.00M |
| Revenue growth (YoY) | — | — | -90.0% | +100.0% |
| Cost of revenue | $61.69M | $113000.00 | $139.14M | $56000.00 |
| Gross profit | $-61.69M | $50.00M | $-134.14M | $9.94M |
| Gross margin | — | 100.0% | -2682.8% | 99.4% |
| R&D | $62.69M | $60.03M | $139.14M | $168.06M |
| SG&A | $12.81M | $17.11M | $28.85M | $53.32M |
| Operating income | $-76.20M | $-37.15M | $-163.89M | $-211.38M |
| Operating margin | — | -74.3% | -3277.8% | -2113.8% |
| EBITDA | $-75.12M | $-27.03M | $-163.75M | $-211.33M |
| EBITDA margin | — | -54.1% | -3275.0% | -2113.3% |
| EBIT | $-75.20M | $-27.15M | $-163.89M | $-211.38M |
| Interest expense | — | — | $0.00 | $7.33M |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-119.28M | $-37.12M | $-156.99M | $-377.74M |
| Net income growth (YoY) | — | +68.9% | -322.9% | -140.6% |
| Profit margin | — | -74.2% | -3139.8% | -3777.4% |